TM-25659
| 中文名称 | TM-25659 |
|---|---|
| 中文同义词 | 3-((2'-(2H-四唑-5-基)-[1,1'-联苯]-4-基)甲基)-2-丁基-5-甲基-6-(吡啶-3-基)-3H-咪唑并[4,5-B]吡啶;化合物 T13169;化合物TM-25659;化合物TM-25659,10 MM DMSO 溶液 |
| 英文名称 | TM-25659 |
| 英文同义词 | TM-25659;3H-Imidazo[4,5-b]pyridine, 2-butyl-5-methyl-6-(3-pyridinyl)-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-;TM 25659,TM25659;3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-5-methyl-6-(pyridin-3-yl)-3H-imidazo[4,5-b]pyridine;TM-25659, 10 mM in DMSO;TAZ Activity Modulator, TM-25659 |
| CAS号 | 260553-97-7 |
| 分子式 | C30H28N8 |
| 分子量 | 500.6 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 260553-97-7.mol |
| 结构式 |  |
TM-25659 性质
| 沸点 | 768.0±70.0 °C(Predicted) |
|---|---|
| 密度 | 1.29±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO：≥ 135 mg/mL (269.68 mM)；水：< 0.1 mg/mL（不溶） |
| 酸度系数(pKa) | 4.15±0.10(Predicted) |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| InChIKey | KCOQNLYGMQJUJD-UHFFFAOYSA-N |
| SMILES | CC1=NC2=C(N=C(CCCC)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)C=C1C6=CN=CC=C6 |
TAZ
TM-25659 (2, 10, 20, 100 μM) enhances nuclear TAZ localization in a dose-dependent manner and attenuates PPARγ-mediated adipocyte differentiation by facilitating PPARγ suppression activity of TAZ.
TM-25659 (2, 10, 50 μM) enhances osteogenic gene expression and thereby increases osteoblast differentiation.
Cell Proliferation Assay
| Cell Line: | 3T3-L1 cells |
| Concentration: | 2, 10, 20, 100 μM |
| Incubation Time: | 6 days |
| Result: | Acted as a suppressor of PPARγ-dependent adipocyte differentiation [1] . |
TM-25659 (50 mg/kg, i.p., every other day for 2 weeks) suppresses bone loss in vivo and decreases weight gain in an obesity model.
TM-25659 has a favourable pharmacokinetic profile in rats. The plasma concentration of TM-25659 declines with an approximate t 1/2 of 7 or 10 h following i.v or p.o. administration respectively. The systemic clearance (CL) is 0.21 L×h -1 ×kg -1 and the volume of distribution at steady-state (1.91 L×h -1 ×kg -1 ) is larger than the volume of total body fluids.
| Animal Model: | C57BL6 mice (4- to 6-week-old ) |
| Dosage: | 50 mg/kg |
| Administration: | I.p., every other day for 2 weeks |
| Result: | Attenuated weight gain in these obese mice [1] . |
| Animal Model: | Adult male Sprague-Dawley rats |
| Dosage: | 10 mg/kg |
| Administration: | I.v. (2, 10 and 30 min), oral (15 and 30 min, and 1, 2, 4 and 8 h) |
| Result: | Oral administration for 4 weeks moderately but significantly attenuated weight gain and partly restored BMD in the OVX rats [1] . |
安全信息
| WGK Germany | WGK 3 |
|---|---|
| 存储类别 | 11 - 可燃固体 |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025/12/22 | HY-112920 | TM-25659 TM-25659 | 260553-97-7 | 5mg | 950元 |
| 2025/12/22 | HY-112920 | TM-25659 TM-25659 | 260553-97-7 | 10mM * 1mLin DMSO | 1050元 |